LOS ANGELES, CA - May 15, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is scheduled to report its first quarter 2025 financial results after the market closes on Thursday, May 15 ...

LOS ANGELES, CA - June 26, 2025 (NEWMEDIAWIRE) - NRx Pharmaceuticals (NASDAQ: NRXP), via its wholly owned subsidiary HOPE Therapeutics (TM), Inc., has signed a binding Letter of Intent to acquire ...

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal ...

NRx Pharmaceuticals NRXP is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for NRXP’s loss per share is pinned at 20 cents. In the absence of a marketed ...

NRXP believes that the demonstration of reduced akathisia in the setting of comparable antidepressant efficacy constitutes a basis for Accelerated FDA Approval of NRX-101.” — Dr. Jonathan ...

NRx Pharmaceuticals NRXP a clinical-stage biopharma company, has filed a patent application for NRX-100, its preservative-free intravenous ketamine formulation targeting suicidal depression. The ...

NRx Pharmaceuticals’ investigational antidepressant has failed to reach statistical significance in reducing depression severity in a phase 2/3 trial, though the biotech is pressing forward to a ...